Communiqués Cereno Scientific AB

Actions

CRNO B

SE0008241558

Marché Fermé - Nasdaq Stockholm Autres places de cotation 18:00:00 19/06/2024			Varia. 5j.	Varia. 1 janv.
4,29 ^SEK	-1,33%		+0,23%	-6,23%

18/06	Cereno Scientific obtient l'approbation de l'UE pour le premier essai sur l'homme de son candidat-médicament antithrombotique	MT
18/06	Cereno Scientific reçoit l'approbation de l'EMA pour lancer le premier essai de phase I chez l'homme avec le nouvel inhibiteur épigénétique d'HDAC, CS014	CI

Communiqués

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

Cereno Scientific granted approval from, EMA to initiate first-in-human Phase I trial with novel epigenetic HDAC inhibitor, CS014	18/06	AQ
Preclinical data for Cereno Scientific's drug candidate CS585 showing high selectivity for the IP receptor presented at the EHA 2024 Hybrid Congress	16/06	AQ
Cereno Scientific moves to new office space at GoCo Health Innovation City in Gothenburg	10/06	AQ
Cereno Scientific initiates collaboration with the Pulmonary and Vascular Research Institute (PVRI)	03/06	AQ
Cereno Scientific to present preclinical data for drug candidate CS585, a novel IP receptor agonist, at the ESC Congress 2024	30/05	AQ
Cereno Scientific participating at BIO 2024, June 3-6, San Diego	28/05	AQ
Cereno Scientific publishes the interim report for Q1 2024 ( January 1-March 31)	23/05	AQ
Cereno Scientific presents at ABGSC Investor Days, May 23	17/05	AQ
Cereno Scientific to present preclinical data for drug candidate CS585 at the EHA 2024 Hybrid Congress	15/05	AQ
Cereno Scientific: Nomination committee appointed ahead of annual general meeting 2025	02/05	AQ
Report from Annual General Meeting 2024 of Cereno Scientific AB	16/04	AQ
Cereno Scientific expands patent protection for epigenetic HDAC inhibitor CS1:s second patent family	11/04	AQ
Cereno Scientific submits Clinical Trial Application (CTA) for first-in-human Phase I study with novel epigenetic HDACi drug candidate CS014	10/04	AQ
Cereno Scientific announces extended patent protection in Europe for CS585 program	09/04	AQ
Cereno Scientific releases Insights Video Season 3 Episode 9 with Dr. Björn Dahlöf, CSO, Cereno Scientific	03/04	AQ
Cereno Scientific participates at the ISHLT 44th Annual meeting and Scientific sessions to expand network and meet with investigators for the Phase II Study in PAH	28/03	AQ
Cereno Scientific releases Insights Video Season 3 Episode 8 with Björn Dahlöf, CSO, Cereno Scientific	27/03	AQ
Cereno Scientific publishes Annual Report for 2023	26/03	AQ
Cereno Scientific participates at the upcoming medical conference ACC.24 to further build presence in the Cardiology community	25/03	AQ
Cereno Scientific announces new patent issued in 25 European countries for Phase II drug candidate CS1	22/03	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Cereno Scientific AB

Actions

CRNO B

SE0008241558

Communiqués

Filtres